The road to taking university research from the lab and translating it into a therapy approved by the Food and Drug Administration is long and perilous. Fiscal 2020 marked significant progress for companies that have licensed Pitt technologies in the therapeutics space in advancing from the pre-clinical development stage to FDA approved clinical trials.
The companies featured in the graph below have raised significant funding to proceed through the arduous clinical trial process and are presenting unique approaches to take on cancer, drug-resistant infections, organ regeneration and more. We will update this periodically as the companies progress from one stage to the next and new ones enter, with the goal of getting full FDA approval so that they can begin making a difference in people’s lives.
If you are interested in learning more about opportunities to license a Pitt therapeutic technology or sponsor research pertaining to specific disease types or therapeutic modalities, contact the Office of Industry and Economic Partnerships at partner@pitt.edu.
